Verification of brain penetration of the unbound fraction of a novel HER2/EGFR dual kinase inhibitor (TAK-285) by microdialysis in rats.
TAK-285, an investigational, orally active HER2/EGRF inhibitor is in clinical development for potential use in HER2 over-expressing metastatic breast cancer. The objective of the present work was to verify the presence of unbound TAK-285 in the rat brain after oral administration by a microdialysis...
| Main Authors: | |
|---|---|
| Format: | Article |
| Published: |
2012
|
| Series: | BRAIN RESEARCH BULLETIN
87 No. 4-5 |
| Subjects: | |
| doi: | 10.1016/j.brainresbull.2012.01.002 |
| mtmt: | 2802853 |
| Online Access: | https://publikacio.ppke.hu/2383 |